Effects of Sodium Butyrate and Its Synthetic Amide Derivative on Liver Inflammation and Glucose Tolerance in an Animal Model of Steatosis Induced by High Fat Diet

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Mattace Raso, Giuseppina ^a   Simeoli, Raffaele ^a   Russo, Roberto ^a   Iacono, Anna ^a   Santoro, Anna ^a   Paciello, Orlando ^a   Ferrante, Maria Carmela ^a   Canani, Roberto Berni ^a   Calignano, Antonio ^a   Meli, Rosaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CHOLESTEROL; CYCLOOXYGENASE 2; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N (1 CARBAMOYL 2 PHENYL ETHYL) BUTYRAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TOLL LIKE RECEPTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; DRUG EFFICACY; DRUG POTENCY; ENERGY METABOLISM; FATTY LIVER; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEPATITIS; HISTOPATHOLOGY; INSULIN RESISTANCE; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WEIGHT GAIN; WESTERN BLOTTING;

ADIPOSE TISSUE; AMIDES; ANIMALS; BUTYRIC ACID; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FATTY LIVER; GLUCOSE; INFLAMMATION; INSULIN RESISTANCE; LIVER; MALE; NF-KAPPA B; RATS; TOLL-LIKE RECEPTORS;

ANIMALIA; RATTUS;

EID: 84879830881     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068626     Document Type: Article

References (40)

1. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ, (2002) The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 217: 133-139. doi:10.1111/j.1574-6968.2002.tb11467.x. PubMed: 12480096.
2. Roy CC, Kien CL, Bouthillier L, Levy E, (2006) Short-chain fatty acids: ready for prime time? Nutr Clin Pract 21: 351-366. doi:10.1177/0115426506021004351. PubMed: 16870803.
3. Ritzaupt A, Wood IS, Hosie Ellis A,. KB, Shirazi-Beechey SP (1998) Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. J Physiol 513: 719-732.
4. Binder HJ, Mehta P, (1989) Short-chain fatty acids stimulate active sodium and chloride absorption in vitro in the rat distal colon. Gastroenterology 96: 989-996. PubMed: 2925072.
5. Berni Canani R, Terrin G, Cirillo P, Castaldo G, Salvatore F, et al. (2004) Butyrate as an effective treatment of congenital chloride diarrhea. Gastroenterology 127: 630-634. doi:10.1053/j.gastro.2004.03.071. PubMed: 15300594.
6. Davie JR, (2003) Inhibition of histone deacetylase activity by butirate activity. J Nutr 133: 2485S-2493S. PubMed: 12840228.
7. Berni Canani R, Di Costanzo M, Leone L, (2012) The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clin Epigenetics 4: 4. doi:10.1186/1868-7083-4-4. PubMed: 22414433.
8. Glozak MA, Sengupta N, Zhang X, Seto E, (2005) Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23. doi:10.1016/j.gene.2005.09.010. PubMed: 16289629.
9. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, et al. (2003) The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278: 11312-11319. doi:10.1074/jbc.M211609200. PubMed: 12496283.
10. Berni Canani R, Costanzo MD, Leone L, Pedata M, Meli R, et al. (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 17: 1519-1528. doi:10.3748/wjg.v17.i12.1519. PubMed: 21472114.
11. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, et al. (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58: 1509-1517. doi:10.2337/db08-1637. PubMed: 19366864.
12. Li H, Gao Z, Zhang J, Ye X, Xu A, et al. (2012) Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes 61: 797-806. doi:10.2337/DB12-DualityInfo. PubMed: 22338096.
13. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635. doi:10.1172/JCI23606. PubMed: 15902306.
14. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116: 3015-3025. doi:10.1172/JCI28898. PubMed: 17053832.
15. Li L, Chen L, Hu L, Liu Y, Sun HY, et al. (2011) Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 54: 1620-1630. doi:10.1002/hep.24552. PubMed: 21809356.
16. Rencurel F, Waeber G, Antoine B, Rocchiccioli F, Maulard P, et al. (1996) Requirement of glucose metabolism for regulation of glucose transporter type 2 (GLUT2) gene expression in liver. Biochem J 314: 903-909. PubMed: 8615787.
17. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, et al. (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300: 1140-1142. doi:10.1126/science.1082889. PubMed: 12750520.
18. De Minicis S, Svegliati-Baroni G, (2011) Fibrogenesis in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 5: 179-187. doi:10.1586/egh.11.28. PubMed: 21476913.
19. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, et al. (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278: 13740-13746. doi:10.1074/jbc.M210689200. PubMed: 12560330.
20. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, et al. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271: 665-668. doi:10.1126/science.271.5249.665. PubMed: 8571133.
21. Tiganis T, (2013) PTP1B and TCPTP- nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J 280: 445-458. doi:10.1111/j.1742-4658.2012.08563.x. PubMed: 22404968.
22. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494-1505. doi:10.1172/JCI26498. PubMed: 16691291.
23. Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, et al. (2010) Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 53: 1795-1806. doi:10.1007/s00125-010-1747-3. PubMed: 20407745.
24. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al. (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139: 323-334. doi:10.1053/j.gastro.2010.03.052. PubMed: 20347818.
25. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, et al. (2009) Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 139: 905-911. doi:10.3945/jn.108.101808. PubMed: 19321579.
26. Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, et al. (2006) Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 26: 613-620. doi:10.1111/j.1478-3231.2006.01265.x. PubMed: 16762007.
27. Woo YC, Xu A, Wang Y, Lam KS, (2013) Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 78: 489-496. doi:10.1111/cen.12095. PubMed: 23134073.
28. Wang YX, (2010) PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res 20: 124-137. doi:10.1038/cr.2010.13. PubMed: 20101262.
29. Gurnell M, (2003) PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol 59: 267-277. doi:10.1046/j.1365-2265.2003.01767.x.
30. Chatterjee PK, (2010) Hepatic inflammation and insulin resistance in pre-diabetes- further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. Br J Pharmacol 160: 1889-1891. doi:10.1111/j.1476-5381.2010.00739.x. PubMed: 20649587.
31. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122. doi:10.1016/j.cell.2006.11.013. PubMed: 17112576.
32. Lin J, Handschin C, Spiegelman BM, (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1: 361-370. doi:10.1016/j.cmet.2005.05.004. PubMed: 16054085.
33. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, et al. (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100: 8466-8471. doi:10.1073/pnas.1032913100. PubMed: 12832613.
34. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273. doi:10.1038/ng1180. PubMed: 12808457.
35. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342. doi:10.1038/nature05354. PubMed: 17086191.
36. Mangian HF, Tappenden KA, (2009) Butyrate increases GLUT2 mRNA abundance by initiating transcription in Caco2-BBe cells. J Parenter Enteral Nutr 33: 607-617. doi:10.1177/0148607109336599. PubMed: 19892901.
37. Beauvieux MC, Roumes H, Robert N, Gin H, Rigalleau V, et al. (2008) Butyrate ingestion improves hepatic glycogen storage in the re-fed rat. BMC Physiol 8: 19. doi:10.1186/1472-6793-8-19. PubMed: 18847460.
38. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, et al. (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44: 645-651. doi:10.1016/0026-0495(95)90123-X. PubMed: 7752914.
39. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, et al. (2006) A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 169: 846-860. doi:10.2353/ajpath.2006.050953. PubMed: 16936261.
40. Sardesai VM, Manning JA, (1967) The determination of tiglycerides in plasma and tissues. Clin Chem 14: 156-161.